Desmoplastic melanoma: Comparison of expression of differentiation antigens and cancer testis antigens

Melanoma Research

Volumn 16, Issue 4, 2006, Pages 347-355

  Lim, Elgene ^b   Browning, Judy ^b   MacGregor, Duncan ^b   Davis, Ian D ^a,b   Cebon, Jonathan S ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Antigen expression; Desmoplastic melanoma; Immunohistochemistry

Indexed keywords

CANCER TESTIS ANTIGEN; DIFFERENTIATION ANTIGEN; GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 4; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PROTEIN S 100; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; DESMOPLASTIC MELANOMA; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; STAINING; TISSUE SECTION;

ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746224212     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000222588.22493.3f     Document Type: Article

References (43)

1. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971; 28:914-936.
2. Smithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming and neurotropic melanoma, a review of 45 cases. Aust NZ J Surg 1990; 60:967-972.
3. Busam KJ, Iversen K, Coplan KC, Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25:197-204.
4. Reed RJ, Leonard DD. Neurotropic melanoma: a variant of desmoplastic melanoma. Am J Surg Pathol 1979; 3:301-311.
5. Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol 1996; 23:205-210.
6. Gyorki DE, Busam K, Panageas K, Brady MS, Coit DG. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 2003; 10:403-407.
7. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-1310.
8. Busam KJ, Antonescu CR, Marghoob AA, Nehal KS, Sachs DL, Shia J, Berwick M. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 2001; 115:856-860.
9. Dunn GP, Bruce AT, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
10. Anstey A, McKee P, Jones EW. Desmoplastic malignant melanoma: a clinicopathological study of 25 cases. Br J Dermatol 1993; 129:359-371.
11. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 1995; 75:478-494.
12. Wharton JM, Carlson JA, Mihm MC Jr. Desmoplastic malignant melanoma: diagnosis of early clinical lesions. Hum Pathol 1999; 30:537-542.
13. Jaroszewski DE, Pockaj BA, Dicaudo DJ, Bite U. The clinical behavior of desmoplastic melanoma. Am J Surg Pathol 2001; 182:590-595.
14. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma, experience with 280 patients. Cancer 1998; 83:1128-1135.
15. Longacre TA, Egbert BM, Rouse RV. Desmoplastic and spindle-cell malignant melanoma: an immunohistochemical study. Am J Surg Pathol 1996; 20:1489-1500.
16. Robson A, Allen P, Hollowood K. S100 expression in cutaneous scars: a potential diagnostic pitfall in the diagnosis of desmoplastic melanoma. Histopathology 2001; 38:135-140.
17. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies Melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J 2000; 32:475-481.
18. Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, et al. Expression of Melan-A(MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998; 22:976-982.
19. Xu X, Chu A, Pasha TL, Elder DE, Zhang PJ. Immunoprofile of MITF, tyrosinase, Melan-A and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol 2002; 26:82-87.
20. Skelton HG, Smith KJ, Laskin WB, McCarthy WF, Gagnier JM, Graham JH, Lupton GP. Desmoplastic malignant melanoma. J Am Acad Dermatol 1995; 32:717-725.
21. Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol 2001; 23:185-189.
22. Boyle JL, Haupt HM, Stern JB, Malthaupt HAB. Tyrosinase expression in malignant melanoma, desmoplastic melanoma and peripheral nerve tumors; an immunohistochemical study. Arch Pathol Lab Med 2002; 126:816-822.
23. Park HR, Min SK. Expression of S100A2 and S100B proteins in epithelial tumors of the skin. J Cutan Pathol 2003; 30:373-378.
24. King R, Googe PB, Weilbaecher KN, Mihm MC Jr, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25:51-57.
25. Koch MB, Shih IM, Weiss SW, Folpe AL. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/ spindle cell melanoma from morphologic mimics. Am J Surg Pathol 2001; 25:58-64.
26. Sundram U, Harvell JD, Rouse RV, Natkunam Y. Expression of the B cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45) and Melan-A. Mod Pathol 2003; 16:802-810.
27. Busam KJ, Zhao H, Coit DG, Kucukgol D, Jungbluth AA, Nobrega J, Viale A. Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J Invest Dermatol 2005; 124:412-418.
28. Simpson AJ, Caballero OL, Jungbluth AA, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-625.
29. Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, Mateo L, et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-Cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 2004; 10:2879-2890.
30. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Vaccine induced CD8+ T cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9:657-662.
31. Scott AM, Cebon J. Clinical promise of tumour immunology. Lancet 1997; 349(Suppl 2):19-22.
32. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73:3-29.
33. Clark WH Jr, Elder DE, Guerry DP 4th, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-1904.
34. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 2004; 10:8396-8404.
35. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92:856-860.
36. Chen YT, Stockert E, Jungbluth AA, Tsang S, Coplan KA, Scanlan MJ, Old LJ. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93:5915-5919.
37. Jungbluth AA, Iverson K, Coplan KA, Kolb D, Stockert E, Chen YT, et al. T311 an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract 2000; 196:235-242.
38. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, Godelaine D. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000; 86:835-841.
39. Bacchi CE, Gown AM. Specificity of antibody HMB-45. Arch Pathol Lab Med 1992; 116:899-900.
40. Boenisch T. Can a more selective application of antigen retrieval facilitate standardization in immunohistochemistry? Appl Immunohistochem Mol Morphol 2004; 12:172-176.
41. Miller RT, Kubier P. Blocking of endogenous avidin-binding activity in immunohistochemistry. The use of egg whites. Appl Immunohistochem 1997; 5:63-66.
42. Miller RT, Kubier P, Reynolds B, Henry T, Turnbow H. Blocking of endogenous avidin-binding activity in immunohistochemistry. The use of skim milk as an economical and effective substitute for commercial biotin solutions. Appl Immunohistochem Mol Morphol 1999; 7:63-65.
43. Mangini J, Li N, Bhawan J. Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol 2002; 24:270-281.